NYSEMKT:IGC IGC Pharma (IGC) Stock Price, News & Analysis $0.45 +0.12 (+36.77%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipSEC FilingsBuy This Stock About IGC Pharma Stock (NYSEMKT:IGC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IGC Pharma alerts:Sign Up Key Stats Today's Range$0.32▼$0.3450-Day Range$0.31▼$0.4652-Week Range$0.25▼$0.48Volume214,616 shsAverage Volume913,992 shsMarket Capitalization$40.50 millionP/E RatioN/ADividend YieldN/APrice Target$3.88Consensus RatingBuy Company Overview IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. Read More IGC Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreIGC MarketRank™: IGC Pharma scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIGC Pharma has received no research coverage in the past 90 days.Read more about IGC Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for IGC Pharma are expected to decrease in the coming year, from ($0.11) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IGC Pharma is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGC Pharma is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGC Pharma has a P/B Ratio of 5.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for IGC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIGC Pharma does not currently pay a dividend.Dividend GrowthIGC Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for IGC. News and Social Media1.4 / 5News SentimentN/A News SentimentIGC Pharma has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.13 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for IGC Pharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for IGC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IGC Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders23.66% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.87% of the stock of IGC Pharma is held by institutions.Read more about IGC Pharma's insider trading history. Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IGC Stock News HeadlinesIGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong ...August 28, 2025 | finance.yahoo.comIGC Pharma expands CALMA Phase 2 trial with Lynn Health Science Institute siteAugust 25, 2025 | msn.comThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history gives him 90% historical confidence that stocks will end 2025 up. However, he also has bad news: the same data also tells him the REAL market crash will likely arrive in 2026.September 2 at 2:00 AM | Chaikin Analytics (Ad)IGC Pharma, Inc.: IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's TrialAugust 19, 2025 | finanznachrichten.deIGC Pharma reports Q1 EPS (2c) vs. (3c) last yearAugust 19, 2025 | msn.comIGC Pharma, Inc.: IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1August 13, 2025 | finanznachrichten.deIGC Pharma highlights preclinical data on IGC-M3August 12, 2025 | msn.comIGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict ...July 12, 2025 | morningstar.comMSee More Headlines IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed this year? IGC Pharma's stock was trading at $0.3360 at the beginning of 2025. Since then, IGC stock has increased by 32.7% and is now trading at $0.4460. How were IGC Pharma's earnings last quarter? IGC Pharma, Inc. (NYSEMKT:IGC) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The business had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.29 million. IGC Pharma had a negative trailing twelve-month return on equity of 122.44% and a negative net margin of 714.16%. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IGC Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that IGC Pharma investors own include Jiuzi (JZXN), Plug Power (PLUG), Avalon GloboCare (ALBT), Ainos (AIMD), Aethlon Medical (AEMD), Aditxt (ADTX) and Adial Pharmaceuticals (ADIL). Company Calendar Last Earnings11/12/2024Today9/02/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEMKT:IGC CIK1326205 Webigcpharma.com Phone(301) 983-0998Fax240-465-0273Employees61Year FoundedN/APrice Target and Rating Average Price Target for IGC Pharma$3.88 High Price Target$4.25 Low Price Target$3.50 Potential Upside/Downside+768.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13 million Net Margins-714.16% Pretax Margin-712.70% Return on Equity-122.44% Return on Assets-88.40% Debt Debt-to-Equity Ratio0.02 Current Ratio1.15 Quick Ratio0.98 Sales & Book Value Annual Sales$1.33 million Price / Sales30.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book5.58Miscellaneous Outstanding Shares90,809,000Free Float54,600,000Market Cap$40.50 million OptionableN/A Beta1.48 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NYSEMKT:IGC) was last updated on 9/2/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHave You Seen This? Trump Schedules 'Stock Market Reset' For Sept. 30Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGC Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.